CD52 and B-cell chronic lymphocytic leukemia: The next biologics were approved early in the 21st century, with humanized monoclonal antibody alemtuzumab (Campath1), which targets CD52 on B, T and NK cells and monocytes, in the therapy of chronic lymphocytic leukemia (2001) [67] (Table 1).